| Clinical Study "Common" Name (formal title) | Number of enrollees | Funding source (pharma/NIH) | Year complete | Primary publication | Full study treatment protocol |
|---|---|---|---|---|---|
| QUASAR [Aflibercept 8 mg in Retinal Vein Occlusion: Primary Endpoint Results from the QUASAR study] | n = 591 |
NCT05850520 Bayer AG |
In progress | Gale R. Aflibercept 8 mg in retinal vein occlusion: Primary endpoint results from the QUASAR study. Presented at: Angiogenesis Meeting 2025; February 8, 2025; Virtual. |
 
|